{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:41:30Z","timestamp":1786977690005,"version":"build-2736575974"},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T00:00:00Z","timestamp":1430352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pain"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Until now, nonivamide\/nicoboxil ointment has not been tested in a randomized trial for the treatment of acute non\u2010specific low back pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This phase III randomized, double\u2010blind, active\u2010 and placebo\u2010controlled, multi\u2010centre trial investigated efficacy, safety and tolerability of topical nicoboxil 2.5%\/nonivamide 0.4% for treatment of acute non\u2010specific low back pain [primary endpoint: pain intensity (\n                      <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                      ) difference between pre\u2010dose baseline and 8\u00a0h after the first application].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0805), 18\u201374\u00a0years of age were treated for up to 4\u00a0days with nicoboxil 2.5%\/nonivamide 0.4%, nicoboxil 2.5%, nonivamide 0.4% or placebo ointment. Pre\u2010dose baseline pain intensity (6.6 on a 0\u2010 to 10\u2010point numerical rating scale) was reduced by 1.049 points with placebo, by 1.428 points with nicoboxil, by 2.252 points with nonivamide and by 2.410 points with nicoboxil\/nonivamide after 8\u00a0h (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001 for nicoboxil\/nonivamide vs. placebo, nicoboxil;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.4171 for nicoboxil\/nonivamide vs. nonivamide). At the end of treatment, the combination provided more pronounced\n                      <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                      reduction (3.540 points) compared with nicoboxil (2.371,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001), nonivamide (3.074,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.0259) and placebo (1.884,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001). Low back mobility scores on Day 1 were better for the combination compared with all other treatments (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.044); on Day 2\u20134, scores were better than for placebo and nicoboxil (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.003). Patients assessed efficacy of the combination as greater than of the comparators (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0\u2264\u00a00.0129). All treatments were tolerated well. No treatment\u2010related serious adverse events were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nicoboxil\/nonivamide ointment is an effective, well\u2010tolerated medication for the treatment of acute non\u2010specific low back pain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejp.719","type":"journal-article","created":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:53:33Z","timestamp":1430441613000},"page":"263-273","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and safety of nicoboxil\/nonivamide ointment for the treatment of acute pain in the low back \u2013 A randomized, controlled trial"],"prefix":"10.1002","volume":"20","author":[{"given":"M.","family":"Gaubitz","sequence":"first","affiliation":[{"name":"Interdisciplinary Diagnostics and Therapy in the Academy for Manual Medicine University M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Outpatient Clinic for Sports Traumatology and Public Health Consultation German Sport University Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Holm","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim RCV GmbH &amp; Co KG Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Richter","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG Ingelheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Pisternick\u2010Ruf","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG Biberach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Weiser","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG Ingelheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,30]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"204","article-title":"Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: Randomized observer\u2010blind multicenter study","volume":"32","author":"Babej\u2010Doelle R.","year":"1994","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/1876386301306010081"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.497720"},{"key":"e_1_2_9_5_1","first-page":"311","article-title":"Definition, Epidemiologie und soziooekonomische Bedeutung des nichtspezifischen Kreuzschmerz","volume":"41","author":"Casser H.\u2010R.","year":"2012","journal-title":"Orthopaede"},{"key":"e_1_2_9_6_1","first-page":"201","article-title":"Clinical experiences with Finalgon ointment in a total of 1040 cases","volume":"13","author":"Chitil W.","year":"1959","journal-title":"Prakt Arzt"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP41375"},{"key":"e_1_2_9_8_1","unstructured":"German Medical Association (B\u00c4K) National Association of Statutory Health Insurance Physicians (KBV) & Association of Scientific Medical Societies (AWMF). (2013).National Disease Management Guideline \u2018Low back pain\u2019 \u2013 Short Version. Version 4. 2011 last amended: August 2013. Available from:http:\/\/www.kreuzschmerz.versorgungsleitlinien.de(accessed on August 28 2014)."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.01.016"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2010.10.002"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00586-007-0379-x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00586-010-1502-y"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.11.030"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000396.pub3"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000066255"},{"key":"e_1_2_9_16_1","first-page":"8","article-title":"A discussion on the use of the rubefacient F\u201081 in physiotherapy","volume":"7","author":"Ward R.S.","year":"1955","journal-title":"Br J Physiother"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2013-0158"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.4817"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(14)60805\u20109"}],"container-title":["European Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejp.719","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejp.719","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejp.719","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejp.719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T22:37:13Z","timestamp":1696286233000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ejp.719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,30]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1002\/ejp.719"],"URL":"https:\/\/doi.org\/10.1002\/ejp.719","archive":["Portico"],"relation":{},"ISSN":["1090-3801","1532-2149"],"issn-type":[{"value":"1090-3801","type":"print"},{"value":"1532-2149","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,30]]}}}